Global Phase 2 Trials Launched for Nipah Virus Vaccine
Why focus: ChAdOx1 viral vector trial launch — sets up classic GS3 Sci-Tech Match-the-Following on vaccine platforms
In News
What Happened
Why It Matters
Background
History & Context
What Changed
- ▶
Vaccine Development Stage: BEFORE - No Nipah vaccine candidate had progressed beyond Phase 1 human trials globally. NOW - The ChAdOx1 NipahB candidate has entered Phase 2 clinical trials in affected regions to generate critical efficacy data.
- ▶
Emergency Preparedness: BEFORE - Outbreak containment relied entirely on supportive care and contact tracing, without any ready-to-deploy vaccine reserves. NOW - SII is creating a 100,000-dose investigational stockpile that can be used for emergency ring-vaccination during future outbreaks.
- ▶
Manufacturing and Supply Chain: BEFORE - Vaccine supply chains for novel zoonotic diseases were often delayed by a lack of localized manufacturing infrastructure. NOW - Leveraging SII's massive production capacity in Pune ensures an immediate, localized supply chain for South Asia.
Prelims Angle
NCERT Connection
Practice Questions
Q1
Correct Statement(s)Which of the following statements is/are correct regarding the Nipah virus and the ChAdOx1 NipahB vaccine candidate? 1. Nipah virus belongs to the paramyxovirus family and is naturally hosted by fruit bats. 2. The ChAdOx1 NipahB vaccine uses a non-replicating adenovirus vector, the same platform utilized for the Oxford-AstraZeneca COVID-19 vaccine.